AbbVie
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease activity of etentamig in combination with a cereblon E3 ligase modulatory drug (CELMoD) agent in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease state will be assessed. Etentamig is an investigational drug being developed for the treatment of R/R MM. Study doctors put the participants in groups called treatment arms. Multiple doses of etentamig in combination with iberdomide will be explored. Each treatment arm receives a different dose of etentamig and iberdomide to determine a tolerable dose. Approximately 135 adult participants with R/R MM will be enrolled in the study in approximately 50 sites worldwide. In phase 1 participants will receive escalating intravenous (IV) etentamig in combination with oral iberdomide. In phase 2 participants will receive IV etentamig at one of two doses in combination with oral iberdomide, as part of the approximately 129 month study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and and monitoring of side effects.
Multiple Myeloma
Etentamig
Iberdomide
PHASE1
B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) or BCMA antibody-drug conjugate (ADC) are allowed.
| Study Type : | INTERVENTIONAL |
| Estimated Enrollment : | 135 participants |
| Masking : | NONE |
| Primary Purpose : | TREATMENT |
| Official Title : | Phase 1/2 Study of Etentamig in Combination With a CELMoD Agent for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma |
| Actual Study Start Date : | 2025-08-07 |
| Estimated Primary Completion Date : | 2036-03 |
| Estimated Study Completion Date : | 2036-03 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
Beverly Hills Cancer Center /ID# 266921
Beverly Hills, California, United States, 90211
RECRUITING
Colorado Blood Cancer Institute /ID# 273751
Denver, Colorado, United States, 80218
RECRUITING
Washington University /ID# 266972
St Louis, Missouri, United States, 63110
RECRUITING
Rutgers Cancer Institute of New Jersey /ID# 266833
New Brunswick, New Jersey, United States, 08901
RECRUITING
Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 270282
New York, New York, United States, 10065
RECRUITING
University Of North Carolina Health Care - Hillsborough Campus /ID# 278230
Hillsborough, North Carolina, United States, 27278
RECRUITING
Swedish Medical Center - Seattle /ID# 268052
Seattle, Washington, United States, 98104
RECRUITING
Blacktown Hospital /ID# 265983
Blacktown, New South Wales, Australia, 2148
RECRUITING
Wollongong Hospital /ID# 265625
Wollongong, New South Wales, Australia, 2500
RECRUITING
The Alfred Hospital /ID# 265981
Melbourne, Victoria, Australia, 3004
RECRUITING
Austin Hospital /ID# 265984
Melbourne, Victoria, Australia, 3084
RECRUITING
Sir Charles Gairdner Hospital /ID# 265985
Nedlands, Western Australia, Australia, 6009
RECRUITING
University Health Network_Princess Margaret Cancer Centre /ID# 275636
Toronto, Ontario, Canada, M5G 2M9
RECRUITING
Jewish General Hospital /ID# 267574
Montreal, Quebec, Canada, H3T 1E2
RECRUITING
Chu de Nice-Hopital Larchet Ii /Id# 266845
Nice, Alpes-Maritimes, France, 06202
RECRUITING
La Timone Hospital /ID# 267053
Marseille, Bouches-du-Rhone, France, 13885
RECRUITING
Chu De Lille - Hopital Claude Huriez /ID# 270193
Lille, Hauts-de-France, France, 59037
RECRUITING
Tours Regional University Hospital - Bretonneau Hospital /ID# 267694
Tours, Indre-et-Loire, France, 37000
RECRUITING
IUCT Oncopole /ID# 266391
Toulouse, Occitanie, France, 31059
RECRUITING
Kumamoto University Hospital /ID# 270530
Kumamoto, Kumamoto, Japan, 860-8556
RECRUITING
Dokkyo Medical University Hospital /ID# 271648
Years, Tochigi, Japan, 321-0293
RECRUITING
Nippon Medical School Hospital /ID# 270254
Bunkyo Ward, Tokyo, Japan, 113-8603
RECRUITING
The Cancer Institute Hospital Of JFCR /ID# 268342
This talk, Tokyo, Japan, 135-8550
RECRUITING
Amsterdam UMC, Location VUmc /ID# 267670
Amsterdam, North Holland, Netherlands, 1081 HV
RECRUITING
University Medical Center Utrecht /ID# 267660
Utrecht, Netherlands, 3584 CX
RECRUITING
Oslo University Hospital Ulleval /ID# 275433
Oslo, Norway, 0450